US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

21.08

-0.7100-3.26%

Volume:550.99K

Turnover:11.61M

Market Cap:1.21B

PE:-8.14

High:22.11

Open:21.73

Low:20.70

Close:21.79

Loading ...

Overview Company News Filings

Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

Viking, Structure rally after Pfizer halts obesity drug development

Obesity Drugmakers Shares Rise After Pfizer Ends Development of Weight-Loss Pill Danuglipron

Press Release: Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Biotech stocks have been hit by 'DOGE' and other fears. Why they're a great value now.

Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

BUZZ-Jefferies looks to Lilly data to reignite interest in obesity stocks

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.

Morgan Stanley Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Structure Therapeutics Is Maintained at Market Outperform by Citizens Capital Markets

William Blair Initiates Structure Therapeutics at Outperform

MT Newswires Live

Structure Therapeutics Initiated at Outperform by William Blair

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

Structure Therapeutics Inc. FY Net Income USD -122.526 Million

THOMSON REUTERS

Structure Therapeutics Inc - Expects Cash to Fund Operations Through 2027

THOMSON REUTERS

Structure Therapeutics Inc. FY Income From Operations USD -158.228 Million

THOMSON REUTERS

Press Release: Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Exicure Acquires GPCR's California Subsidiary, Enters Into Licensing Agreement

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GPCR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GPCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":21.08,"timestamp":1750968000000,"preClose":21.79,"halted":0,"volume":550992,"delay":0,"floatShares":48739903,"shares":57536749,"eps":-2.590061,"marketStatus":"Pre-Mkt","change":-0.71,"latestTime":"06-27 04:41:22 EDT","open":21.73,"high":22.105,"low":20.7032,"amount":11605435.950576,"amplitude":0.064332,"askPrice":23.24,"askSize":100,"bidPrice":18.96,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.590061,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751031000000},"marketStatusCode":1,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":21.08,"postHourTrading":{"tag":"盘后","latestPrice":21.08,"preClose":21.08,"latestTime":"19:24 EDT","volume":6234,"amount":131412.82,"timestamp":1750980261797},"volumeRatio":0.5663039528729803,"impliedVol":0.7167,"impliedVolPercentile":0.1365},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","floatShares":48739903,"roa":"-17.24%","roe":"-22.85%","lyrEps":-2.327592,"volumeRatio":0.5663039528729803,"shares":57536749,"dividePrice":0,"high":22.105,"amplitude":0.064332,"preClose":21.79,"low":20.7032,"week52Low":13.22,"pbRate":"1.47","week52High":47.48,"institutionHeld":0,"latestPrice":21.08,"eps":-2.590061,"divideRate":0,"volume":550992,"delay":0,"ttmEps":-2.590061,"open":21.73,"prevYearClose":27.12,"prevWeekClose":21.73,"prevMonthClose":21.76,"prevQuarterClose":17.31,"fiveDayClose":21.62,"twentyDayClose":22.2,"sixtyDayClose":17.31},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GPCR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527964071","title":"Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill","url":"https://stock-news.laohu8.com/highlight/detail?id=2527964071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527964071?lang=en_us&edition=fundamental","pubTime":"2025-04-14 22:35","pubTimestamp":1744641325,"startTime":"0","endTime":"0","summary":"Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to disco...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/smaller-obesity-drugmakers-jump-after-pfizer-scraps-weight-loss-pill?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/smaller-obesity-drugmakers-jump-after-pfizer-scraps-weight-loss-pill?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3581.USD","BK4533","SG9999001176.SGD","LU0868494617.USD","LU0456855351.SGD","LU0122379950.USD","BK4581","LU0306806265.USD","LU0306807586.USD","LU0289739699.SGD","LU0985481810.HKD","SG9999001176.USD","BK4007","IE0002270589.USD","SG9999011175.SGD","LU1883839398.USD","VKTX","BK4534","SG9999013999.USD","LU0321505868.SGD","PFE","SG9999002232.USD","IE00BLSP4239.USD","LU0225771236.USD","LU1023059063.AUD","BK4568","LU0170899867.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU0058720904.USD","LU0234572021.USD","LU1057294990.SGD","GPCR","LU1894683264.USD","IE00BBT3K403.USD","BK4592","LU1894683348.USD","IE000M9KFDE8.USD","LU1066051498.USD","BK4585","BK4588","LU0321505439.SGD","IE00BLSP4452.SGD","BK4599","BK4550","BK4139","IE00B19Z3B42.SGD","LU0225284248.USD","SG9999002224.SGD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2527621521","title":"Viking, Structure rally after Pfizer halts obesity drug development","url":"https://stock-news.laohu8.com/highlight/detail?id=2527621521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527621521?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:50","pubTimestamp":1744638656,"startTime":"0","endTime":"0","summary":"Shares of Viking Therapeutics (VKTX) are up 13% to $25.17 in early trading while Structure Therapeutics (GPCR) is up 7% to 17.02. Published first o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/viking-structure-rally-after-pfizer-halts-obesity-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/viking-structure-rally-after-pfizer-halts-obesity-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","SG9999011175.SGD","LU0289739699.SGD","SG9999001176.SGD","IE00BBT3K403.USD","BK4588","LU1066053197.SGD","SG9999002232.USD","LU1066051498.USD","BK4533","LU0170899867.USD","IE00B19Z3B42.SGD","BK4007","IE00BLSP4239.USD","BK4568","IE00B19Z3581.USD","VKTX","LU0868494617.USD","BK4599","LU0225284248.USD","LU0321505868.SGD","LU0122379950.USD","LU0985481810.HKD","LU0306806265.USD","GPCR","SG9999013999.USD","BK4592","IE00BLSP4452.SGD","LU1057294990.SGD","LU0306807586.USD","BK4581","SGXZ57979304.SGD","IE0002270589.USD","LU0234572021.USD","LU0321505439.SGD","BK4550","SG9999002224.SGD","LU1894683264.USD","LU1023059063.AUD","LU0225771236.USD","SG9999001176.USD","LU1894683348.USD","SG9999003800.SGD","IE000M9KFDE8.USD","LU1883839398.USD","LU0456855351.SGD","BK4139","LU0058720904.USD","BK4585"],"gpt_icon":0},{"id":"2527137975","title":"Obesity Drugmakers Shares Rise After Pfizer Ends Development of Weight-Loss Pill Danuglipron","url":"https://stock-news.laohu8.com/highlight/detail?id=2527137975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527137975?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:48","pubTimestamp":1744638490,"startTime":"0","endTime":"0","summary":"","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nFWN3QQ01Z:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Obesity Drugmakers Shares Rise After Pfizer Ends Development of Weight-Loss Pill Danuglipron","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","IE00BLSP4452.SGD","BK4550","IE00BBT3K403.USD","BK4592","SGXZ57979304.SGD","LU1023059063.AUD","SG9999001176.SGD","BK4533","LU1883839398.USD","LU1057294990.SGD","BK4581","LU0122379950.USD","BK4599","SG9999003800.SGD","SG9999013999.USD","IE00B19Z3B42.SGD","LU0321505868.SGD","BK4007","NVO","BK4588","IE000M9KFDE8.USD","SG9999002232.USD","LU0456855351.SGD","LU1066051498.USD","VKTX","BK4585","LU0170899867.USD","LU0225284248.USD","IE00B19Z3581.USD","LU1894683264.USD","LU0306807586.USD","LU1894683348.USD","BK4534","LU1066053197.SGD","LU0868494617.USD","SG9999001176.USD","SG9999002224.SGD","LU0306806265.USD","LU0321505439.SGD","GPCR","BK4568","SG9999011175.SGD","LU0985481810.HKD","IE00BLSP4239.USD","IE0002270589.USD","LU0289739699.SGD","LLY","LU0058720904.USD","LU0234572021.USD"],"gpt_icon":1},{"id":"2522725673","title":"Press Release: Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522725673","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522725673?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year. Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025. Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028. SOUTH SAN FRANCISCO, Calif., March 27, 2025  -- Septerna, Inc. , a biotechnology company pioneering a new era of G protein-coupled receptor  drug discovery, today provided a corporate overview complete with upcoming milestones and reported fourth quarter and full year 2024 financial results.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","03160","BK4604","BK4588","BK4555","GPCR","SEPN","BK4099","TM","BK4585","BK4599"],"gpt_icon":0},{"id":"2522371948","title":"Biotech stocks have been hit by 'DOGE' and other fears. Why they're a great value now.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522371948","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522371948?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:40","pubTimestamp":1743075600,"startTime":"0","endTime":"0","summary":"Investors' deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approval and M&A. Potential personnel cutbacks at the U.S. Food and Drug Administration also seem troubling. But maybe not. The retirement buyout offers for government employees exclude FDA staff who review drug approvals. \"So far, the FDA cuts have been related to medical technology and not in crucial drug regulatory roles,\" Yee said. He added that several companies have recently told him they've noticed no notable changes or delays at the FDA.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4007","LU0868494617.USD","LU2023250843.SGD","US30Y.BOND","BK4588","LU1037948897.HKD","SG9999001440.SGD","US12M.BOND","LU0965509101.SGD","LU1162221912.USD","SG9999002232.USD","LU1093756325.SGD","US3Y.BOND","BK4139","LU2361044865.SGD","SWTX","US5Y.BOND","US6M.BOND","LU1929549753.HKD","IE00BN8TJ469.HKD","IE00BBT3K403.USD","LU0289739699.SGD","LU1430594728.SGD","LU1989771016.USD","BK4535","INSM","GPCR","MRK","LU2089984988.USD","LU1037948541.HKD","LU0070302665.USD","SG9999001176.SGD","US2Y.BOND","NPV","IE0002141913.USD","BHVN","SG9999014567.USD","DNLI","PFE","LU0306807586.USD","US7Y.BOND","IE00B2B36J28.USD","US10Y.BOND","LU0861579265.USD","LU1023059063.AUD","LU0320765992.SGD","LU1934455863.HKD","FTC","BK4548"],"gpt_icon":1},{"id":"2519819833","title":"Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2519819833","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519819833?lang=en_us&edition=fundamental","pubTime":"2025-03-14 23:26","pubTimestamp":1741965998,"startTime":"0","endTime":"0","summary":"We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Septerna, Inc.  stands against other top insider purchases last month.How will new tariffs impact the U.S. economy?What’s next on President Trump’s geopolitical agenda?These are some of the concerning questions influencing market conditions.According to J.P. Morgan’s chief global economist, Bruce Kasman, there is about a 40% chance of a U.S. recession and a risk of lasting damage to the country’s reputation as an investment destination, writes Reuters.“Where we stand now is with a heightened concern about the U.S. economy,” Kasman said to reporters in Singapore on Wednesday.Additionally, Goldman Sachs lowered its 2025-end target for the broader market. “The proximate causes of the market decline are the jump in policy uncertainty largely related to tariffs, concerns about the economic growth outlook, and a positioning unwind, especially among hedge funds,” analysts","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/septerna-inc-sepn-among-top-152638628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2471134523.USD","BK4550","LU2471134879.HKD","LU0106831901.USD","LU2750360997.AUD","LU2237443978.SGD","IE00BFXG1179.USD","LU2237443622.USD","LU1868836757.USD","SEPN","BK4504","LU0061475181.USD","LU1868837300.USD","IE00BSNM7G36.USD","LU1868837136.USD","BK4552","BK4127","LU2471134952.CNY","LU2471134796.USD","GPCR","LU2237443382.USD","LU2237438978.USD","IE00B19Z3B42.SGD","LU0096364046.USD","IE0034235188.USD","BK4588","IE0004091025.USD","BK4585","LU1868836914.USD","LU2237443465.HKD","BK4533","IE0004086264.USD","LU1791807156.HKD","LU2750360641.GBP","IE0002270589.USD","BK4516","IE00B19Z3581.USD","LU2237443549.SGD","LU1668664300.SGD","LU2237443895.HKD","BK4599","LU1868836591.USD","BK4007"],"gpt_icon":0},{"id":"2517613054","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517613054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517613054?lang=en_us&edition=fundamental","pubTime":"2025-03-06 18:30","pubTimestamp":1741257042,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fate Therapeutics (FATE – Research Report), Organon (OGN – Resear...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-fate-therapeutics-fate-organon-ogn-and-structure-therapeutics-inc-sponsored-adr-gpcr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-fate-therapeutics-fate-organon-ogn-and-structure-therapeutics-inc-sponsored-adr-gpcr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","FATE","GPCR","BK4137","BK4007","OGN","BK4139","HCSG","BK4585","LU2065170008.USD","LU2065171311.SGD","BK4599","LU2065169927.USD","LU2065171402.SGD","BK4559"],"gpt_icon":0},{"id":"2517945314","title":"BUZZ-Jefferies looks to Lilly data to reignite interest in obesity stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2517945314","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517945314?lang=en_us&edition=fundamental","pubTime":"2025-03-05 23:21","pubTimestamp":1741188086,"startTime":"0","endTime":"0","summary":"BUZZ-Jefferies looks to Lilly data to reignite interest in obesity stocks** Brokerage Jefferies says investor sentiment on obesity stocks is \"mixed\" at best, but hopes that positive data from Eli Lilly's LLY.N oral obesity drug will bring investors back into this space** LLY shares fell 8% after company's Q3 weight-loss drug sales missed estimates, but have since recovered; its stock is up 19% YTD ** LLY is expected to report late-stage data on its experimental obesity drug, orforglipron, by April** \"We would like to see positive LLY orfo data help drive the obesity comps back up and bring investors back into this space\" - Jefferies ** Outside LLY as the leader, Jefferies says it likes Amgen AMGN.O and Structure Therapeutics GPCR.O, which are both expected to report data on their experimental drugs in H2 ** AMGN up 11.7%, GPCR down 46.6% and LLY up 14.9% in the past 12 months  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL3N3PO11S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0198837287.USD","LU1712237335.SGD","LU0203202063.USD","SG9999017495.SGD","LU2237443382.USD","LU0203201768.USD","LU1868836591.USD","LU1551013342.USD","LU2468319806.SGD","LU0456855351.SGD","IE00B2B36J28.USD","LU1988902786.USD","LU0385154629.USD","LLY","LU0289739699.SGD","LU1023059063.AUD","LU2106854487.HKD","LU0097036916.USD","LU1093756325.SGD","LU2491050154.USD","LU0823416689.USD","LU0354030438.USD","LU2242646821.SGD","LU1061106388.HKD","SG9999018857.SGD","IE00BJJMRZ35.SGD","BK4581","LU2237443465.HKD","IE0002141913.USD","LU1093756168.USD","LU1868836757.USD","BK4139","LU2324357040.USD","LU0094547139.USD","LU0672654240.SGD","SG9999014880.SGD","LU1720051108.HKD","LU1623119135.USD","LU0320765992.SGD","BK4588","SG9999001440.SGD","GPCR","AMGN","SGXZ99366536.SGD","SG9999015952.SGD","SG9999001176.SGD","LU2461242641.AUD","LU1057294990.SGD","LU0471298694.HKD","LU1720051017.SGD"],"gpt_icon":1},{"id":"2516634659","title":"AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634659","media":"Blockhead","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516634659?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:04","pubTimestamp":1741014273,"startTime":"0","endTime":"0","summary":"AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/abbvie-stock-weight-loss-drug-gubra-licensing-deal/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["SG9999001176.SGD","LU1267930730.SGD","LU1804176565.USD","LU2361044865.SGD","LU2237443549.SGD","LU2237443465.HKD","LU1244550221.USD","LU2106854487.HKD","LU2324357040.USD","LU1720051017.SGD","LU0122379950.USD","LU0708994859.HKD","LU1496350502.SGD","NVO.AU","BK4532","LU0553294199.USD","LU0234570918.USD","BK4139","LU1974910355.USD","IE0009355771.USD","IE00B42XCP33.USD","LU0006306889.USD","ABBV","IE00BJJMRZ35.SGD","BK4007","LU2491050154.USD","IE00BKVL7J92.USD","GPCR","LU1917777945.USD","LU1934455863.HKD","LU0109391861.USD","VKTX","LU1720051108.HKD","LU1839511570.USD","SG9999015945.SGD","LU1280957306.USD","LU2133065610.SGD","LU0094547139.USD","LU0203202063.USD","LU1868836757.USD","LU2023250504.SGD","LU0820561818.USD","LU1035775433.USD","BK4599","IE0002141913.USD","BK4581","SG9999014914.USD","LU1244550494.USD"],"gpt_icon":1},{"id":"2516092633","title":"Morgan Stanley Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516092633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516092633?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:08","pubTimestamp":1741007333,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Terence Flynn maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and set a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR"],"gpt_icon":0},{"id":"2516379506","title":"Structure Therapeutics Is Maintained at Market Outperform by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379506","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379506?lang=en_us&edition=fundamental","pubTime":"2025-02-28 23:58","pubTimestamp":1740758280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GPCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 10:58 ET (15:58 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","LENZ"],"gpt_icon":0},{"id":"2514329134","title":"William Blair Initiates Structure Therapeutics at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329134","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329134?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:05","pubTimestamp":1740747928,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) has an average rating of buy and mean price target of $81.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","GPCR"],"gpt_icon":0},{"id":"2514326997","title":"Structure Therapeutics Initiated at Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2514326997","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514326997?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:16","pubTimestamp":1740744960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GPCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 07:16 ET (12:16 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","LENZ"],"gpt_icon":0},{"id":"2514318237","title":"U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp","url":"https://stock-news.laohu8.com/highlight/detail?id=2514318237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514318237?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:07","pubTimestamp":1740726458,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp Feb 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autodesk, Coca-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL3N3PJ0KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BE","GPCR","MNST","LU0965509010.AUD","RLAY","ICUI","IE00B1BXHZ80.USD","COGT","CRBP","FOLD","ALHC","IE0002141913.USD","TERN","IOVA","ORA","BIOA","IE00BFTCPJ56.SGD","CARS","NTLA","JAMF","LU0106261372.USD","IE00BJJMRZ35.SGD","PSBD","ADSK","LU1037948541.HKD","LU0823414478.USD","STWD","RUN","LU0175139822.USD","HRL","LU0012050646.USD","NTAP","RKT","TASK","LU2506952097.USD","CCOI","LU1992135472.HKD","NUVL","ARRY","LU0289960550.SGD","KO","BK4226","ALT","IE00BBT3K403.USD","VAC","DUOL","SJM"],"gpt_icon":1},{"id":"2514998330","title":"Structure Therapeutics Inc. FY Net Income USD -122.526 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514998330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514998330?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX8F26A1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2514355504","title":"Structure Therapeutics Inc - Expects Cash to Fund Operations Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2514355504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514355504?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX8F26A1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2514233054","title":"Structure Therapeutics Inc. FY Income From Operations USD -158.228 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514233054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514233054?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX8F26A1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2514233058","title":"Press Release: Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2514233058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514233058?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690300,"startTime":"0","endTime":"0","summary":"Aleniglipron  ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025. Oral small molecule amylin receptor agonist  Investigational New Drug -enabling activities underway; First-in-human Phase 1 initiation anticipated by year-end 2025. Strong year-end financial position with cash, cash equivalent and short-term investments of $883.5 million. SAN FRANCISCO, Feb. 27, 2025  -- Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","LENZ","BK4139","BK4007"],"gpt_icon":1},{"id":"2507062300","title":"Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2507062300","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507062300?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:30","pubTimestamp":1738243800,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Jan. 30, 2025  -- Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/structure-therapeutics-participate-multiple-upcoming-133000019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","GPCR","BK4599","BK4137","HCSG","BK4139"],"gpt_icon":0},{"id":"2505402066","title":"Exicure Acquires GPCR's California Subsidiary, Enters Into Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2505402066","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505402066?lang=en_us&edition=fundamental","pubTime":"2025-01-23 16:52","pubTimestamp":1737622351,"startTime":"0","endTime":"0","summary":"Exicure  said late Wednesday it has agreed to acquire all shares of GPCR Therapeutics USA, a subsidiary of GPCR Therapeutics, a Korean corporation.In connection with the deal, Exicure and GPCR made a licensing and collaboration agreement to further develop and commercialize certain GPCR technologies, the company said.Financial terms were not disclosed.Under the agreement, Exicure is to pay GPCR milestone payments upon reaching specific milestone events relating to clinical trials, marketing authorizations, and net sales, as well as a recurring royalty payment based on at least 10% of net sales, the company said.Shares of Exicure were up more than 46% in Wednesday's after-hours activity.Price: 15.21, Change: +4.84, Percent Change: +46.67","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GPCR","BK4599","BK4139","XCUR","BK4007"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GPCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"GPCR","fiscalQuarterEnding":"2025/03","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2025-02-27","symbol":"GPCR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-11-13","symbol":"GPCR","fiscalQuarterEnding":"2024/09","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GPCR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GPCR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":14,"updateTime":1746244800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GPCR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GPCR","date":"2025-06-26","current":-8.747555,"percent":0.963605,"low":-50.180001,"twenty":-24.920519,"median":-20.436031,"eighty":-14.681108,"high":-6.622278,"avg":-20.756908,"sd":8.182495,"marketCap":1253725760},"quantilePoints":[{"date":"2023-02-03","current":-25.001825,"twenty":-43.272389,"median":-43.272389,"eighty":-32.310051,"marketCap":951294422},{"date":"2023-02-10","current":-22.116999,"twenty":-35.964163,"median":-23.496907,"eighty":-22.21316,"marketCap":841529681},{"date":"2023-02-17","current":-21.285207,"twenty":-24.521021,"median":-22.645883,"eighty":-21.915061,"marketCap":809880847},{"date":"2023-02-24","current":-23.36709,"twenty":-23.715192,"median":-22.645883,"eighty":-21.847749,"marketCap":889094402},{"date":"2023-03-03","current":-25.530709,"twenty":-24.422936,"median":-22.718004,"eighty":-21.972757,"marketCap":971417957},{"date":"2023-03-10","current":-22.636267,"twenty":-24.85566,"median":-22.790125,"eighty":-22.063149,"marketCap":861287334},{"date":"2023-03-17","current":-22.232392,"twenty":-24.422936,"median":-22.70358,"eighty":-22.09392,"marketCap":845920270},{"date":"2023-03-24","current":-21.876596,"twenty":-23.762311,"median":-22.568955,"eighty":-21.891982,"marketCap":832382619},{"date":"2023-03-31","current":-16.960589,"twenty":-23.565181,"median":-22.314128,"eighty":-21.634271,"marketCap":870434396},{"date":"2023-04-06","current":-17.823234,"twenty":-23.376706,"median":-22.232392,"eighty":-21.285207,"marketCap":914706175},{"date":"2023-04-14","current":-17.473898,"twenty":-23.36709,"median":-22.116999,"eighty":-18.643102,"marketCap":896777933},{"date":"2023-04-21","current":-17.210114,"twenty":-23.194,"median":-22.059302,"eighty":-17.623613,"marketCap":883240282},{"date":"2023-04-28","current":-17.815518,"twenty":-23.078607,"median":-21.876596,"eighty":-17.586227,"marketCap":914310203},{"date":"2023-05-05","current":-17.709107,"twenty":-22.982446,"median":-21.689083,"eighty":-17.623613,"marketCap":908849077},{"date":"2023-05-12","current":-17.00755,"twenty":-22.790125,"median":-21.491953,"eighty":-17.586227,"marketCap":956079400},{"date":"2023-05-19","current":-15.32957,"twenty":-22.780509,"median":-20.818827,"eighty":-17.473898,"marketCap":861751761},{"date":"2023-05-26","current":-19.808636,"twenty":-22.761276,"median":-19.808636,"eighty":-17.466769,"marketCap":1113542462},{"date":"2023-06-02","current":-21.830342,"twenty":-22.668962,"median":-20.674586,"eighty":-17.472472,"marketCap":1227192672},{"date":"2023-06-09","current":-23.110075,"twenty":-22.668962,"median":-21.38858,"eighty":-17.563702,"marketCap":1299132872},{"date":"2023-06-16","current":-21.061141,"twenty":-22.668962,"median":-21.491953,"eighty":-17.586212,"marketCap":1183952020},{"date":"2023-06-23","current":-21.782692,"twenty":-22.640113,"median":-21.568882,"eighty":-17.608538,"marketCap":1224514048},{"date":"2023-06-30","current":-27.561913,"twenty":-22.772816,"median":-21.571672,"eighty":-17.623492,"marketCap":1549392931},{"date":"2023-07-07","current":-24.451072,"twenty":-23.059375,"median":-21.612515,"eighty":-17.625039,"marketCap":1374517018},{"date":"2023-07-14","current":-21.428724,"twenty":-23.103781,"median":-21.707815,"eighty":-17.644282,"marketCap":1204615694},{"date":"2023-07-21","current":-23.069233,"twenty":-23.103781,"median":-21.780436,"eighty":-17.700571,"marketCap":1296836908},{"date":"2023-07-28","current":-23.552536,"twenty":-23.333385,"median":-21.782692,"eighty":-17.727736,"marketCap":1324005814},{"date":"2023-08-04","current":-21.592094,"twenty":-23.51737,"median":-21.782692,"eighty":-17.804907,"marketCap":1213799550},{"date":"2023-08-11","current":-19.978813,"twenty":-23.374783,"median":-21.781564,"eighty":-17.817061,"marketCap":1123108978},{"date":"2023-08-18","current":-16.072919,"twenty":-23.333385,"median":-21.735043,"eighty":-17.644282,"marketCap":1053531639},{"date":"2023-08-25","current":-16.66259,"twenty":-23.197654,"median":-21.646551,"eighty":-17.586168,"marketCap":1092182818},{"date":"2023-09-01","current":-16.458249,"twenty":-23.185384,"median":-21.592094,"eighty":-17.468195,"marketCap":1078788845},{"date":"2023-09-08","current":-16.680105,"twenty":-23.150918,"median":-21.568882,"eighty":-17.319402,"marketCap":1093330873},{"date":"2023-09-15","current":-18.326514,"twenty":-23.110075,"median":-21.460338,"eighty":-17.211393,"marketCap":1201248026},{"date":"2023-09-22","current":-19.937893,"twenty":-23.078607,"median":-21.067948,"eighty":-17.309925,"marketCap":1306869070},{"date":"2023-09-29","current":-21.876218,"twenty":-23.069233,"median":-21.012104,"eighty":-17.319402,"marketCap":1433920470},{"date":"2023-10-06","current":-37.165618,"twenty":-23.194,"median":-21.285207,"eighty":-17.395476,"marketCap":2436094784},{"date":"2023-10-13","current":-44.162453,"twenty":-23.552536,"median":-21.525005,"eighty":-17.459473,"marketCap":2894716299},{"date":"2023-10-20","current":-45.222784,"twenty":-23.852048,"median":-21.571672,"eighty":-17.466769,"marketCap":2964217822},{"date":"2023-10-27","current":-47.275909,"twenty":-23.892891,"median":-21.592094,"eighty":-17.469621,"marketCap":3098794020},{"date":"2023-11-03","current":-48.538851,"twenty":-24.328544,"median":-21.646551,"eighty":-17.490333,"marketCap":3181576088},{"date":"2023-11-10","current":-38.273225,"twenty":-24.864943,"median":-21.735043,"eighty":-17.514986,"marketCap":2508695101},{"date":"2023-11-17","current":-27.570058,"twenty":-25.04304,"median":-21.781564,"eighty":-17.543453,"marketCap":2122673903},{"date":"2023-11-24","current":-32.691508,"twenty":-27.365869,"median":-21.782692,"eighty":-17.586168,"marketCap":2516984612},{"date":"2023-12-01","current":-35.337541,"twenty":-28.3175,"median":-21.830342,"eighty":-17.593664,"marketCap":2720707940},{"date":"2023-12-08","current":-37.983573,"twenty":-33.138225,"median":-21.904522,"eighty":-17.623452,"marketCap":2924431267},{"date":"2023-12-15","current":-37.177707,"twenty":-34.105722,"median":-22.049686,"eighty":-17.625039,"marketCap":2862386033},{"date":"2023-12-22","current":-20.939825,"twenty":-34.105722,"median":-22.001606,"eighty":-17.644282,"marketCap":1612198995},{"date":"2023-12-29","current":-23.446258,"twenty":-34.065552,"median":-22.068918,"eighty":-17.684898,"marketCap":1805174329},{"date":"2024-01-05","current":-26.187472,"twenty":-34.000259,"median":-22.102574,"eighty":-17.702705,"marketCap":2016225834},{"date":"2024-01-12","current":-28.789086,"twenty":-33.67371,"median":-22.232392,"eighty":-17.746366,"marketCap":2216529345},{"date":"2024-01-19","current":-27.710368,"twenty":-33.290514,"median":-22.259189,"eighty":-17.804907,"marketCap":2133476670},{"date":"2024-01-26","current":-26.745867,"twenty":-33.138225,"median":-22.283013,"eighty":-17.817061,"marketCap":2059217807},{"date":"2024-02-02","current":-28.598724,"twenty":-32.691508,"median":-22.44298,"eighty":-17.823234,"marketCap":2201872991},{"date":"2024-02-09","current":-29.823387,"twenty":-32.667396,"median":-22.576119,"eighty":-17.835432,"marketCap":2296162205},{"date":"2024-02-16","current":-28.427399,"twenty":-32.293017,"median":-22.636267,"eighty":-17.890184,"marketCap":2188682272},{"date":"2024-02-23","current":-26.035182,"twenty":-31.181303,"median":-22.647193,"eighty":-17.91403,"marketCap":2004500750},{"date":"2024-03-01","current":-25.743294,"twenty":-31.092467,"median":-22.775115,"eighty":-17.959972,"marketCap":1982027673},{"date":"2024-03-08","current":-22.849791,"twenty":-30.933832,"median":-22.849791,"eighty":-18.031985,"marketCap":1759251085},{"date":"2024-03-15","current":-18.291889,"twenty":-29.823387,"median":-22.775115,"eighty":-18.031985,"marketCap":1639319082},{"date":"2024-03-22","current":-22.815466,"twenty":-29.601298,"median":-22.761276,"eighty":-18.070517,"marketCap":2044722039},{"date":"2024-03-28","current":-22.311113,"twenty":-29.398245,"median":-22.645883,"eighty":-18.070517,"marketCap":1999521939},{"date":"2024-04-05","current":-20.434088,"twenty":-29.301795,"median":-22.601624,"eighty":-18.089549,"marketCap":1831303011},{"date":"2024-04-12","current":-20.928042,"twenty":-29.107626,"median":-22.568955,"eighty":-18.098906,"marketCap":1875571150},{"date":"2024-04-19","current":-18.81184,"twenty":-29.061939,"median":-22.455039,"eighty":-18.224405,"marketCap":1685917123},{"date":"2024-04-26","current":-20.267704,"twenty":-28.863962,"median":-22.311113,"eighty":-18.256547,"marketCap":1816391638},{"date":"2024-05-03","current":-20.281918,"twenty":-28.794162,"median":-22.289169,"eighty":-18.270537,"marketCap":1817665530},{"date":"2024-05-10","current":-20.105056,"twenty":-28.789086,"median":-22.270856,"eighty":-18.288305,"marketCap":1801815151},{"date":"2024-05-17","current":-17.123915,"twenty":-28.636796,"median":-22.232392,"eighty":-18.098906,"marketCap":1672681180},{"date":"2024-05-24","current":-18.288418,"twenty":-28.476893,"median":-22.116999,"eighty":-18.062811,"marketCap":1786430959},{"date":"2024-05-31","current":-16.11295,"twenty":-28.435013,"median":-22.068918,"eighty":-17.902107,"marketCap":1573929112},{"date":"2024-06-07","current":-26.55105,"twenty":-28.381712,"median":-22.102574,"eighty":-17.902107,"marketCap":2593533072},{"date":"2024-06-14","current":-24.646705,"twenty":-28.337752,"median":-22.198735,"eighty":-17.932407,"marketCap":2407514791},{"date":"2024-06-21","current":-22.312809,"twenty":-28.3175,"median":-22.24579,"eighty":-17.974375,"marketCap":2179537500},{"date":"2024-06-28","current":-18.680713,"twenty":-28.3175,"median":-22.24579,"eighty":-18.00318,"marketCap":1824750754},{"date":"2024-07-05","current":-17.874111,"twenty":-28.267548,"median":-22.198735,"eighty":-17.932407,"marketCap":1745961056},{"date":"2024-07-12","current":-20.408464,"twenty":-28.068249,"median":-22.08815,"eighty":-17.932407,"marketCap":1993519219},{"date":"2024-07-15","current":-20.943017,"twenty":-28.006064,"median":-22.078534,"eighty":-17.941595,"marketCap":2045734877},{"date":"2024-08-02","current":-17.387286,"twenty":-27.943879,"median":-22.068918,"eighty":-17.908069,"marketCap":1698407510},{"date":"2024-08-09","current":-16.461364,"twenty":-27.802578,"median":-21.942986,"eighty":-17.823234,"marketCap":1607962532},{"date":"2024-08-16","current":-20.792004,"twenty":-27.780694,"median":-21.876596,"eighty":-17.821691,"marketCap":2088244945},{"date":"2024-08-23","current":-22.295452,"twenty":-27.74971,"median":-21.929398,"eighty":-17.823234,"marketCap":2239243758},{"date":"2024-08-30","current":-21.822777,"twenty":-27.716713,"median":-21.953525,"eighty":-17.863936,"marketCap":2191770646},{"date":"2024-09-06","current":-21.851252,"twenty":-27.691332,"median":-21.926349,"eighty":-17.874111,"marketCap":2194630472},{"date":"2024-09-13","current":-22.944669,"twenty":-27.671026,"median":-21.901472,"eighty":-17.880178,"marketCap":2304447790},{"date":"2024-09-20","current":-22.067657,"twenty":-27.608415,"median":-21.926349,"eighty":-17.902107,"marketCap":2216365150},{"date":"2024-09-27","current":-23.650834,"twenty":-27.565171,"median":-22.001606,"eighty":-17.941595,"marketCap":2375371475},{"date":"2024-10-04","current":-24.083644,"twenty":-27.536769,"median":-22.068918,"eighty":-18.000093,"marketCap":2418840830},{"date":"2024-10-11","current":-22.130301,"twenty":-27.481934,"median":-22.12365,"eighty":-18.029927,"marketCap":2222656767},{"date":"2024-10-18","current":-22.563112,"twenty":-27.163394,"median":-22.116999,"eighty":-18.055104,"marketCap":2266126122},{"date":"2024-10-25","current":-21.333018,"twenty":-26.967956,"median":-22.11226,"eighty":-18.070517,"marketCap":2142581639},{"date":"2024-10-31","current":-21.560813,"twenty":-26.932422,"median":-22.097835,"eighty":-18.080033,"marketCap":2165460247},{"date":"2024-11-08","current":-21.839862,"twenty":-26.875803,"median":-22.107521,"eighty":-18.096607,"marketCap":2193486542},{"date":"2024-11-15","current":-19.500107,"twenty":-26.820843,"median":-22.068288,"eighty":-18.16223,"marketCap":2155736838},{"date":"2024-11-22","current":-15.573182,"twenty":-26.740791,"median":-22.039183,"eighty":-18.047398,"marketCap":1721615252},{"date":"2024-11-29","current":-17.170432,"twenty":-26.702879,"median":-21.932448,"eighty":-17.923218,"marketCap":1898191276},{"date":"2024-12-06","current":-16.181125,"twenty":-26.575564,"median":-21.883856,"eighty":-17.833409,"marketCap":1788823393},{"date":"2024-12-13","current":-16.424567,"twenty":-26.524021,"median":-21.851252,"eighty":-17.817061,"marketCap":1815735909},{"date":"2024-12-20","current":-15.523314,"twenty":-26.386717,"median":-21.835102,"eighty":-17.715324,"marketCap":1716102339},{"date":"2024-12-27","current":-15.30059,"twenty":-26.269962,"median":-21.822777,"eighty":-17.687076,"marketCap":1691480250},{"date":"2025-01-03","current":-14.601342,"twenty":-26.20397,"median":-21.78933,"eighty":-17.625803,"marketCap":1614178343},{"date":"2025-01-10","current":-14.005686,"twenty":-26.17605,"median":-21.782692,"eighty":-17.604018,"marketCap":1548328570},{"date":"2025-01-17","current":-13.974608,"twenty":-26.160821,"median":-21.780436,"eighty":-17.514986,"marketCap":1544892930},{"date":"2025-01-24","current":-14.482211,"twenty":-26.10752,"median":-21.737354,"eighty":-17.469621,"marketCap":1601008389},{"date":"2025-01-31","current":-15.7046,"twenty":-26.035182,"median":-21.700984,"eighty":-17.381485,"marketCap":1736143575},{"date":"2025-02-07","current":-15.549212,"twenty":-26.032644,"median":-21.680405,"eighty":-17.295679,"marketCap":1718965373},{"date":"2025-02-14","current":-12.622728,"twenty":-25.9819,"median":-21.605123,"eighty":-17.234446,"marketCap":1395442576},{"date":"2025-02-21","current":-12.115125,"twenty":-25.903236,"median":-21.581883,"eighty":-17.21037,"marketCap":1339327118},{"date":"2025-02-28","current":-11.819887,"twenty":-25.84482,"median":-21.567582,"eighty":-17.171628,"marketCap":1306688535},{"date":"2025-03-07","current":-11.01217,"twenty":-25.735679,"median":-21.559435,"eighty":-17.124089,"marketCap":1349277189},{"date":"2025-03-14","current":-9.547313,"twenty":-25.689992,"median":-21.491953,"eighty":-17.045645,"marketCap":1169794078},{"date":"2025-03-21","current":-10.235281,"twenty":-25.609403,"median":-21.417887,"eighty":-16.960589,"marketCap":1254088063},{"date":"2025-03-28","current":-9.33203,"twenty":-25.527539,"median":-21.321628,"eighty":-16.93886,"marketCap":1143416369},{"date":"2025-04-04","current":-7.64253,"twenty":-25.480594,"median":-21.202701,"eighty":-16.831205,"marketCap":936408691},{"date":"2025-04-11","current":-7.043483,"twenty":-25.340669,"median":-21.061141,"eighty":-16.666093,"marketCap":863009847},{"date":"2025-04-17","current":-8.672143,"twenty":-25.329214,"median":-21.042579,"eighty":-16.563339,"marketCap":1062562954},{"date":"2025-04-25","current":-11.068331,"twenty":-25.25285,"median":-20.951128,"eighty":-16.426861,"marketCap":1356158331},{"date":"2025-05-02","current":-12.790591,"twenty":-25.171712,"median":-20.933479,"eighty":-16.305436,"marketCap":1567180008},{"date":"2025-05-09","current":-12.551909,"twenty":-25.070517,"median":-20.891345,"eighty":-16.181125,"marketCap":1537935156},{"date":"2025-05-16","current":-9.774326,"twenty":-25.068859,"median":-20.829252,"eighty":-16.056814,"marketCap":1400885752},{"date":"2025-05-23","current":-9.895696,"twenty":-25.0453,"median":-20.693431,"eighty":-15.839386,"marketCap":1418280862},{"date":"2025-05-30","current":-9.000467,"twenty":-25.01052,"median":-20.672234,"eighty":-15.745511,"marketCap":1289973912},{"date":"2025-06-06","current":-8.619091,"twenty":-25.001825,"median":-20.550917,"eighty":-15.544032,"marketCap":1235314001},{"date":"2025-06-13","current":-8.920177,"twenty":-24.996225,"median":-20.487391,"eighty":-15.387426,"marketCap":1278466562},{"date":"2025-06-20","current":-8.679308,"twenty":-24.952868,"median":-20.449033,"eighty":-14.973238,"marketCap":1243944513},{"date":"2025-06-26","current":-8.747555,"twenty":-24.920519,"median":-20.436031,"eighty":-14.681108,"marketCap":1253725760}],"updateTime":1751013682313}}}